Windtree Therapeutics (WINT) has provided an announcement.
Windtree Therapeutics, Inc. has experienced a shift in its Board of Directors, with Daniel Geffken and Leslie J. Williams resigning on August 13, 2024, for reasons not stemming from any disagreements with company operations or practices. To fill the gaps, the Board has appointed Jed Latkin and Saundra Pelletier, who have been deemed independent under Nasdaq rules and will also hold committee chair positions. Additionally, Mark Strobeck, Ph.D. has been named the lead independent director, with all newly appointed directors serving until the 2024 annual stockholders’ meeting or until their earlier departure. Compensation for the new directors will follow the company’s established policy, and they are set to sign standard indemnification agreements.
For detailed information about WINT stock, go to TipRanks’ Stock Analysis page.
